PureCycle Technologies, Inc.
PCT Nasdaq Plastic Materials, Synth Resins & Nonvulcan Elastomers Financials FY2020βFY2025
What PureCycle Technologies, Inc. does
No business description yet.
- Legal name
- PureCycle Technologies, Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K Β· Feb 26, 2026
- Accession Β· CIK
- 0001193125-26-076801
0001830033
Revenue and margins
PureCycle Technologies, Inc. had $8.4M of revenue in fiscal 2025.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was β$184M in fiscal 2025, β2,197.3% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
PureCycle Technologies, Inc. returned $4.9M to shareholders in fiscal 2025. The diluted share count rose 9.1%.
Balance sheet
Cash, debt and the ratios that show how comfortably PureCycle Technologies, Inc. can carry it.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $201M | $162M | $122M | $15.7M | $170M |
| Debt incl. finance leases | $250M | $250M | $9.1M | $12.9M | β |
| Debt / equity | 0.7x | 0.5x | 0.0x | 0.1x | β |
| Interest coverage | β | β | β3.6x | β2.6x | β2.8x |
| Current ratio | 9.0x | 6.2x | 2.9x | 0.6x | 2.3x |
| Quick ratio | 9.0x | 6.2x | 2.8x | 0.5x | 2.1x |
| Total assets | $665M | $861M | $1.0B | $798M | $923M |
| Total liabilities | $283M | $350M | $619M | $618M | $572M |
| Shareholders' equity | $382M | $511M | $420M | $180M | $45.9M |
| Net debt (β = net cash) | $48.8M | $87.1M | β$112M | β$2.8M | β |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
| Test | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β |
| F-score | β / 3 | 4 / 7 | 4 / 8 | 3 / 8 | 1 / 8 | 4 / 7 |
| Accruals ratio | β8.6% | β4.3% | β2.5% | β0.7% | β15.7% | β4.6% |
| Altman Z'' | β | β | β | β0.43 | β3.81 | β3.33 |
6 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | β$4.1M | β$6.7M | $2.6M | $0.0M | $0.0M | $8.4M |
| Net interest income | β$4.1M | β$6.7M | $2.6M | β | β | β |
| Research and development | $0.6M | $3.7M | $4.4M | $6.6M | $6.5M | $5.9M |
| Operating income | β | β | β | β$114M | β$145M | β$181M |
| Interest expense | $4.1M | $7.5M | $2.3M | $31.4M | $56.9M | $64.4M |
| Pretax income | β$53.0M | β$77.5M | β$84.7M | β$101M | β$289M | β$182M |
| Income tax | $0.0M | $0.0M | $0.0M | $0.7M | β$0.1M | $1.0M |
| Net income | β$53.0M | β$77.5M | β$84.7M | β$102M | β$289M | β$183M |
| Net income to common | β$56.3M | β$77.5M | β$84.7M | β$102M | β$289M | β$194M |
| Diluted EPS | β$1.96 | β$0.79 | β$0.55 | β$0.63 | β$1.75 | β$1.21 |
| Diluted shares | 0.03B | 0.10B | 0.16B | 0.16B | 0.17B | 0.18B |
| Cash flow | ||||||
| Cash from operations | β$18.0M | β$54.5M | β$65.5M | β$94.9M | β$145M | β$143M |
| Capital expenditure | $29.8M | $137M | $287M | $154M | $55.6M | $40.8M |
| Free cash flow | β$47.8M | β$192M | β$353M | β$249M | β$200M | β$184M |
| Depreciation and amortization | $1.9M | $2.3M | $3.6M | $15.9M | $31.3M | $29.1M |
| Stock-based compensation | $5.6M | $22.6M | $10.8M | $11.8M | $11.7M | $14.9M |
| Share buybacks | $0.0M | $1.7M | $1.6M | $1.4M | $1.6M | $4.9M |
| Dividends and buybacks | $0.0M | $1.7M | $1.6M | $1.4M | $1.6M | $4.9M |
| Balance sheet | ||||||
| Cash and short-term investments | $64.5M | $201M | $162M | $122M | $15.7M | $170M |
| Total debt | β | $250M | $250M | $9.1M | $12.9M | β |
| Current assets | $64.9M | $345M | $236M | $163M | $53.9M | $198M |
| Current liabilities | $33.1M | $38.5M | $38.3M | $55.6M | $90.9M | $87.6M |
| Inventory | β | β | β | $4.8M | $8.1M | $13.8M |
| Property and equipment, net | $74.1M | $225M | $506M | $639M | $674M | $658M |
| Total assets | $408M | $665M | $861M | $1.0B | $798M | $923M |
| Total liabilities | $296M | $283M | $350M | $619M | $618M | $572M |
| Preferred stock | β | β | β | $0.0M | $0.0M | β |
| Shareholders' equity | $112M | $382M | $511M | $420M | $180M | $45.9M |
| Margins | ||||||
| Operating margin | β | β | β | β | β | β2,171.6% |
| EBITDA margin | β | β | β | β | β | β1,823.1% |
| Net margin | 1,290.6% | 1,165.1% | β3,208.9% | β | β | β2,185.1% |
| FCF margin | 1,163.3% | 2,884.8% | β13,353.5% | β | β | β2,197.3% |
| Net interest share of revenue | 100.0% | 100.0% | 100.0% | β | β | β |
| Returns | ||||||
| Return on capital | β | β | β | β29.2% | β64.6% | β |
| Return on capital employed | β | β | β | β11.6% | β20.5% | β21.7% |
| Return on equity | β47.4% | β31.4% | β19.0% | β21.8% | β96.3% | β161.3% |
| Return on assets | β13.0% | β14.5% | β11.1% | β10.7% | β31.5% | β21.2% |
| Return on tangible equity | β50.4% | β20.3% | β16.6% | β24.2% | β160.2% | β422.5% |
| Growth | ||||||
| Revenue growth | β | β | β | β100.0% | β | β |
| Share count change | β | 258.4% | 51.6% | 5.0% | 0.8% | 9.1% |
| Financial health | ||||||
| Debt / equity | β | 0.7x | 0.5x | 0.0x | 0.1x | β |
| Interest coverage | β | β | β | β3.6x | β2.6x | β2.8x |
| Current ratio | 2.0x | 9.0x | 6.2x | 2.9x | 0.6x | 2.3x |
| Quick ratio | 2.0x | 9.0x | 6.2x | 2.8x | 0.5x | 2.1x |
| Capital allocation | ||||||
| Capex / revenue | β726.1% | β2,065.4% | 10,874.3% | β | β | 488.9% |
| Stock comp / revenue | β137.0% | β340.3% | 410.5% | β | β | 178.8% |
| Quality scores | ||||||
| Piotroski F-score | β | 4.0 | 4.0 | 3.0 | 1.0 | 4.0 |
| Altman Z'' | β | β | β | β0.4 | β3.8 | β3.3 |
| Accruals ratio | β8.6% | β4.3% | β2.5% | β0.7% | β15.7% | β4.6% |
Source: SEC EDGAR XBRL filings (CIK 0001830033). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.